There are 2789 resources available
1305P - Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer
Presenter: Hugo Arasanz
Session: ePoster Display
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1245P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Presenter: Ruifen Tian
Session: ePoster Display
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display
697P - Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Presenter: Carolina Alves Costa Silva
Session: ePoster Display
698P - Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Presenter: Jonathan Rosenberg
Session: ePoster Display
699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Presenter: Jonathan Rosenberg
Session: ePoster Display